Lulu Wang, Ph.D., represents life sciences clients in patent litigation, contentious proceedings before the U.S. Patent and Trademark Office (USPTO), patent prosecution, and strategic counseling. With a doctorate in neurobiology from Harvard Medical School, she focuses on combining technical expertise and legal insight into compelling strategies tailored to client needs.
Lulu manages and defends patent portfolios involving diverse technologies, including antibodies, biologics, cancer biology, diagnostics, endocrinology, gene editing and CRISPR, gene therapy and AAV, immunology and immuno-oncology, microbiology, neuroscience and neurodegeneration (such as Alzheimer’s and Parkinson’s diseases), recombinant molecules, and synthetic biology.
Lulu represents companies in post-grant proceedings such as inter partes reviews (IPRs) before the USPTO. She also conducts patent due diligence, prepares and prosecutes patent applications, and provides freedom-to-operate and patentability opinions.
Lulu’s litigation experience includes Biologics Price Competition and Innovation Act (BPCIA) and Abbreviated New Drug Application (ANDA) litigation; developing infringement, validity, and claim construction positions; preparing for depositions; and working with experts.
Articles in the National Law Review database by Oulu (Lulu) Wang, Ph.D.